RESUMEN
DAB(389)IL-2 (denileukin diftitox, ONTAK) is a cytokine-targeted fusion protein that delivers the catalytic domain of diphtheria toxin to lymphoma cells expressing the interleukin-2 receptor (IL-2R). In phase I and phase III studies of DAB(389)IL-2 in patients with cutaneous T-cell lymphoma (CTCL), non-Hodgkin's lymphoma, and Hodgkin's disease in which premedications were limited to diphenhydramine and acetaminophen, acute infusion-related hypersensitivity reactions occurred in 70% of patients and vascular leak syndrome (VLS) in 27%, resulting in discontinuation of therapy in 29% of patients. There was no correlation between the dose or half-life of DAB(389)IL-2 and the occurrence of hypersensitivity events or VLS. To explore whether steroid premedication would improve the tolerability of DAB(389)IL-2, we treated 15 patients with CTCL with either dexamethasone or prednisone prior to each dose of DAB(389)IL-2. The incidence of acute infusion events was significantly decreased, with only three patients experiencing acute infusion events (one grade 4) and only two patients developing clinically apparent VLS. Grade 3 skin rash occurred in two patients and moderately severe asthenia in nine patients. A significantly improved response rate of 60% was noted with the use of steroid premedication compared to prior studies in which steroids were prohibited. We conclude that steroid premedication significantly improves the tolerability of DAB(389)IL-2 without compromising the clinical response.
Asunto(s)
Toxina Diftérica/efectos adversos , Hipersensibilidad a las Drogas/prevención & control , Glucocorticoides/uso terapéutico , Inmunosupresores/efectos adversos , Inmunotoxinas/efectos adversos , Interleucina-2/efectos adversos , Linfoma Cutáneo de Células T/tratamiento farmacológico , Proteínas Recombinantes de Fusión/efectos adversos , Neoplasias Cutáneas/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Terapia Combinada , Dexametasona/uso terapéutico , Toxina Diftérica/uso terapéutico , Hipersensibilidad a las Drogas/etiología , Femenino , Humanos , Inmunosupresores/uso terapéutico , Inmunotoxinas/uso terapéutico , Interleucina-2/uso terapéutico , Linfocitos/inmunología , Linfoma Cutáneo de Células T/metabolismo , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Prednisona/uso terapéutico , Premedicación , Proteínas Recombinantes de Fusión/uso terapéutico , Neoplasias Cutáneas/metabolismo , Síndrome , Resultado del TratamientoRESUMEN
BACKGROUND: Denileukin diftitox, a fusion protein targeting both malignant and normal activated lymphocytes, has been shown previously to have antipsoriatic activity. However, the ideal dosing regimen for treating psoriasis was not established. OBJECTIVE: We examined the safety and efficacy of denileukin diftitox in patients with severe plaque-type psoriasis. METHODS: This was a cohort dose-escalation trial. Patients were administered denileukin diftitox on 3 consecutive days every other week. Patients were evaluated for toxicity, improvement in psoriasis, immunogenicity, and serum levels. RESULTS: Thirty-five patients were treated at 3 dose levels. Eight patients had a 50% decrease or more in Psoriasis Area and Severity Index score from baseline (0/10 at 0.5 microg/kg per day, 1/10 at 1.5 microg/kg per day, and 7/15 at 5 microg/kg per day). Adverse events primarily consisted of constitutional events and skin reactions. CONCLUSIONS: The potential antipsoriatic activity of denileukin diftitox demonstrated in this study was comparable to that observed in other psoriasis studies with this agent. However, this dosing regimen was better tolerated than the dosing regimen used in the last study with denileukin diftitox in psoriasis patients.
Asunto(s)
Toxina Diftérica , Interleucina-2 , Proteínas/administración & dosificación , Psoriasis/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto , Proteínas/inmunología , Proteínas Recombinantes de Fusión , SeguridadRESUMEN
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions. PATIENTS AND METHODS: Patients with biopsy-proven CTCL that expressed CD25 on > or = 20% of lymphocytes were assigned to one of two dose levels (9 or 18 microg/kg/d) of denileukin diftitox administered 5 consecutive days every 3 weeks for up to 8 cycles. Patients were monitored for toxicity and clinical efficacy, the latter assessed by changes in disease burden and quality of life measurements. Antibody levels of antidenileukin diftitox and anti-interleukin-2 and serum concentrations of denileukin diftitox were also measured. RESULTS: Overall, 30% of the 71 patients with CTCL treated with denileukin diftitox had an objective response (20% partial response; 10% complete response). The response rate and duration of response based on the time of the first dose of study drug for all responders (median of 6.9 months with a range of 2.7 to more than 46.1 months) were not statistically different between the two doses. Adverse events consisted of flu-like symptoms (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hypotension, dyspnea, chest pain, and back pain), and a vascular leak syndrome (hypotension, hypoalbuminemia, edema). In addition, 61% of the patients experienced transient elevations of hepatic transaminase levels with 17% grade 3 or 4. Hypoalbuminemia occurred in 79%, including 15% with grade 3 or 4 changes. Tolerability at 9 and 18 microg/kg/d was similar, and there was no evidence of cumulative toxicity. CONCLUSION: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.
Asunto(s)
Antineoplásicos/uso terapéutico , Toxina Diftérica , Interleucina-2 , Linfoma Cutáneo de Células T/tratamiento farmacológico , Proteínas/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Esquema de Medicación , Femenino , Humanos , Inmunohistoquímica , Linfoma Cutáneo de Células T/metabolismo , Linfoma Cutáneo de Células T/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Proteínas/administración & dosificación , Proteínas/farmacocinética , Receptores de Interleucina-2/metabolismo , Proteínas Recombinantes de Fusión , Inducción de RemisiónRESUMEN
We examined the effects of CTLA4Ig treatment in an experimental model of myasthenia gravis (EAMG) induced by immunizing Lewis rats with purified Torpedo acetylcholine receptor (AChR). During a primary response, CTLA4Ig treatment inhibited AChR antibody production profoundly, and induced a shift of AChR antibody isotypes from the normally predominant IgG2 isotype pattern toward an IgG1 response. Challenge of rats previously treated with CTLA4Ig produced markedly lower AChR antibody responses compared to untreated controls, persistent inhibition of the IgG2b isotype, and no development of EAMG. Treatment of a secondary AChR response with CTLA4Ig or with DAB389IL2 (which kills lymphocytes expressing IL2 receptors) inhibited AChR antibody responses, and clinical EAMG moderately. In contrast, combined treatment with CTLA4Ig plus DAB389IL2 strikingly inhibited AChR antibody levels, and completely prevented EAMG. Our results suggest that the therapeutic benefit of CTLA4Ig may be due to overall inhibition of AChR antibody production as well as a shift in the antibody isotype repertoire.
Asunto(s)
Antígenos de Diferenciación/uso terapéutico , Toxina Diftérica/uso terapéutico , Inmunoconjugados , Inmunosupresores/uso terapéutico , Inmunoterapia , Interleucina-2/uso terapéutico , Miastenia Gravis/terapia , Abatacept , Animales , Formación de Anticuerpos/efectos de los fármacos , Antígenos CD , Autoanticuerpos/inmunología , Antígeno CTLA-4 , Sinergismo Farmacológico , Quimioterapia Combinada , Femenino , Inmunoglobulina G/análisis , Isotipos de Inmunoglobulinas/análisis , Ratas , Ratas Endogámicas Lew , Receptores Colinérgicos/inmunología , Proteínas Recombinantes de Fusión/uso terapéutico , Valores de ReferenciaRESUMEN
To identify the risk factors and attributable mortality associated with superinfections in febrile neutropenic patients with hematologic malignancies, we prospectively evaluated 333 episodes of fever and neutropenia by means of univariate and multivariate analyses. Superinfection was defined as any infection either occurring during antibiotic therapy or developing within 1 week after discontinuation of antibiotic therapy. Of 333 episodes, 46 (13.8%) were defined as superinfection; these episodes occurred in 46 patients. The risk factors for superinfection in the multivariate analysis were longer duration of profound neutropenia (P < .0001), lack of use of quinolones as prophylaxis (P < .0001), presence of a central venous catheter (P = .02), and persistence of fever after 3 days of antibiotic therapy (P = .02). The crude mortality rate among patients with superinfection was 48%, and the attributable mortality rate was 24% (95% confidence interval, 3%-45%). Identifying risk factors for superinfections in neutropenic patients might allow clinical practices to reduce the negative impact of this complication.
Asunto(s)
Infecciones por Bacterias Gramnegativas/mortalidad , Infecciones por Bacterias Grampositivas/mortalidad , Leucemia/mortalidad , Linfoma/mortalidad , Micosis/mortalidad , Neutropenia/mortalidad , Sobreinfección , Adolescente , Adulto , Niño , Preescolar , Humanos , Lactante , Leucemia/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Persona de Mediana Edad , Neutropenia/tratamiento farmacológico , Estudios Prospectivos , Factores de RiesgoRESUMEN
Schistosomiasis causes pathology in an estimated 200 million individuals. Clinical disease is caused by a complex immunopathologic response to the parasite ova, which are deposited in the host tissues. This immunopathologic response is caused by T lymphocytes which express the high-affinity IL-2 receptor (IL-2R). DAB389IL-2 is a diphtheria toxin-IL-2 fusion toxin protein which functionally inactivates or kills cells which bear the high-affinity IL-2R. DAB389IL-2 has been used in man to suppress IL-2R-dependent immune reactivity. Therefore, we reasoned that DAB389IL-2 might suppress immunopathology in schistosomiasis. In these studies we assessed the in vitro and in vivo effects of DAB389IL-2 on the development of immunopathology in murine schistosomiasis. DAB389IL-2 suppressed IL-2, lectin mitogen (Con A), and soluble Schistosoma mansoni egg antigen-induced lymphocyte proliferation and in vitro granuloma formation. In addition, DA-B389IL-2 suppressed in vitro IL-2R expression. DA-B389IL-2 also suppressed the development of granulomas and collagen deposition in vivo in the livers of infected animals. Therefore, DAB389IL-2 may have potential for the targeted reduction of immunopathology due to schistosomiasis in man.
Asunto(s)
Toxina Diftérica/uso terapéutico , Inmunosupresores/uso terapéutico , Inmunotoxinas/uso terapéutico , Interleucina-2/uso terapéutico , Esquistosomiasis mansoni/inmunología , Esquistosomiasis mansoni/patología , Animales , Antígenos Helmínticos/farmacología , División Celular/efectos de los fármacos , División Celular/inmunología , Concanavalina A/farmacología , Epítopos , Granuloma/etiología , Granuloma/patología , Interleucina-2/farmacología , Parasitosis Hepáticas/patología , Parasitosis Hepáticas/terapia , Activación de Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Receptores de Interleucina-2/efectos de los fármacos , Proteínas Recombinantes de Fusión , Esquistosomiasis mansoni/terapiaRESUMEN
Smooth muscle cell accumulation is a key feature of restenosis that may be inhibited by the delivery of receptor-targeted cytotoxins. DAB389EGF is a recombinant fusion protein in which the receptor-binding domain of diphtheria toxin has been replaced by human epidermal growth factor (EGF). We investigated the effectiveness of DAB389EGF to inhibit neointimal hyperplasia in the balloon-injured rat carotid artery. Incubation of rat carotid arteries with 125I-labeled EGF revealed extensive EGF binding sites in the neointima of balloon-injured arteries. Sixty rats subsequently received either saline or DAB389EGF (total dose, 0.15 mg) delivered immediately following balloon injury either systemically, via 14-day continuous osmotic pump infusion, or locally, via 30-minute intraluminal incubation. The effect of both treatment strategies was measured 2 weeks after injury by cross-sectional morphometric analysis of intimal area, the ratio of intimal/medial area (I/M), and the percent luminal narrowing (%LN). In addition, proliferative activity was assessed by immunostaining for the presence of the proliferating cell nuclear antigen (PCNA). Compared with controls, systemic delivery of fusion toxin significantly reduced intimal area, I/M, and %LN by 40%, 40%, and 29%, respectively. However, these rats exhibited 2% weight loss, indicating mild systemic toxicity. Local, intraluminal administration of DAB389EGF yielded a more pronounced reduction in intimal area, I/M, and %LN by 74%, 79%, and 72%, respectively. This inhibitory effect was preserved at 3 weeks postinjury, and PCNA immunostaining of locally treated arteries revealed a virtual absence of proliferative activity in the neointima and media at this timepoint. In contrast to systemically treated rats, rats receiving fusion toxin locally gained weight at a rate similar to controls, indicating avoidance of systemic toxicity. We conclude that DAB389EGF is a potent inhibitor of neointimal hyperplasia in vivo and that whereas an inhibitory effect may be achieved by systemic delivery, local delivery appears to be more potent, avoids systemic toxicity, and thus represents a feasible strategy to preempt restenosis.
Asunto(s)
Toxina Diftérica/farmacología , Factor de Crecimiento Epidérmico/farmacología , Receptores ErbB/fisiología , Músculo Liso Vascular/efectos de los fármacos , Proteínas Recombinantes de Fusión/farmacología , Animales , Toxina Diftérica/administración & dosificación , Factor de Crecimiento Epidérmico/administración & dosificación , Factor de Crecimiento Epidérmico/metabolismo , Hiperplasia , Masculino , Músculo Liso Vascular/patología , Antígeno Nuclear de Célula en Proliferación/análisis , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes de Fusión/administración & dosificaciónRESUMEN
In this paper we report a eight-year prospective study designed to further characterize incidence, epidemiology, specific syndromes, treatment and prognosis associated with fungal infections in neutropenic patients. During the study period 30 fungal infections were diagnosed in 30 patients among 313 episodes of fever and neutropenia (10%). There were 15 cases of candidiasis, 5 pulmonary aspergillosis, 3 sinusitis by Aspergillus fumigatus, 5 infections by Fusarium sp., one infection by Trichosporon sp., and one infection due to Rhodotorula rubra. Blood cultures were positive in 18 cases (60%). The predisposing factors for fungal infection in multivariate analysis were the presence of central venous catheter (p < 0.001), longer duration of profound (< 100/mm3) neutropenia (p < 0.001), the use of corticosteroids (p < 0.001), gram-positive bacteremia (p = 0.002) and younger age (p = 0.03). In multivariate analysis only recovery of the neutropenia (p < 0.001) was associated with good prognosis whereas the diagnosis of infection by Fusarium sp. (p = 0.006) was strongly associated with a poor outcome. The death rate was 43%. There was no statistically significant difference in the death rate between patients who did receive (52%) or did not receive (50%) antifungal treatment. Identifying patients at risk, specific syndromes and prognostic factors may help to reduce the high mortality associated with disseminated fungal infections in neutropenic patients.
Asunto(s)
Micosis/complicaciones , Neutropenia/complicaciones , Adolescente , Adulto , Antifúngicos/administración & dosificación , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Micosis/diagnóstico , Micosis/tratamiento farmacológico , Neutropenia/sangre , Pronóstico , Estudios Prospectivos , Factores de RiesgoRESUMEN
The role of the new triazoles in the treatment of disseminated fungal infections in neutropenic patients is at present under scrutiny. Six neutropenic patients with disseminated fungal infections were treated with amphotericin B during neutropenia and itraconazole after bone marrow recovery. There were three pulmonary aspergillomas, one Aspergillus fumigatus sinusitis, one Fusarium-mycosis and one disseminated candidosis. Four patients were cured of the infection. This approach seems to be safe and effective in the treatment of disseminated fungal infections in neutropenic patients, with the advantages of low side-effects and the possibility of early discharge from hospital.
Asunto(s)
Anfotericina B/administración & dosificación , Itraconazol/administración & dosificación , Micosis/tratamiento farmacológico , Adulto , Niño , Femenino , Humanos , Leucemia/complicaciones , Masculino , Micosis/etiología , Neutropenia/complicacionesRESUMEN
Smooth muscle cell proliferation in the intima of arteries is a principal event associated with vascular narrowing after balloon angioplasty and bypass surgery. Techniques for limiting smooth muscle cell proliferation, however, have not as yet yielded any therapeutic benefit for these conditions. This may reflect the present lack of sufficiently potent and specific inhibitors of smooth muscle cell proliferation. DAB389 EGF is a genetically engineered fusion protein in which the receptor-binding domain of diphtheria toxin has been replaced by human epidermal growth factor. We evaluated the effect of this fusion toxin on human vascular smooth muscle cells in culture. Incubation of proliferating cells with DAB389 EGF yielded a dose-dependent inhibition of protein synthesis, as assessed by uptake of [3H]leucine, with an IC50 of 40 pM. The cytotoxic effect was inhibited in the presence of excess EGF or with monoclonal antibody to the EGF receptor. We further studied the effect of the fusion toxin on smooth muscle cell outgrowth from human atherosclerotic plaque. Outgrowth was markedly inhibited after as little as 1 h of exposure to the fusion protein. Furthermore, complete inhibition of proliferation of cells within the plaque could be attained. These results demonstrate that DAB389 EGF is highly cytotoxic to human smooth muscle cells proliferating in culture and can prevent smooth muscle cell outgrowth from "growth-stimulated" human atherosclerotic plaque. DAB389 EGF may therefore be of therapeutic value in vascular diseases characterized by smooth muscle cell accumulation.
Asunto(s)
Arteriosclerosis/patología , Toxina Diftérica/farmacología , Factor de Crecimiento Epidérmico/farmacología , Receptores ErbB/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Proteínas Recombinantes de Fusión/farmacología , División Celular/efectos de los fármacos , Células Cultivadas , Receptores ErbB/fisiología , Humanos , Músculo Liso Vascular/patologíaRESUMEN
Three cases are reported of disseminated infection due to Fusarium species in severely neutropenic patients. The clinical findings in all patients included fever, painful disseminated nodular skin lesions and severe myalgia. The outcome was fatal despite early administration of amphotericin B. The portal of entry of the organism was probably the nasal sinus in two cases.
Asunto(s)
Fusarium , Micosis/microbiología , Neutropenia/complicaciones , Adolescente , Niño , Femenino , Humanos , Huésped Inmunocomprometido , Masculino , Micosis/tratamiento farmacológico , Micosis/patología , Neutropenia/microbiologíaRESUMEN
DAB486IL-2 is an interleukin-2 receptor-specific cytotoxin which selectively targets and kills cells which bear the high-affinity form of the IL-2 receptor. Since elimination of activated T lymphocytes may be useful in the treatment of rheumatoid arthritis, the effect of DAB486IL-2 treatment in an animal model of arthritis was investigated. We demonstrated that rats treated with DAB486IL-2 during the induction phase of disease have delayed onset of symptoms and significantly reduced severity of inflammation as well as a depressed proliferative response to mycobacterial stimulation in vitro. In addition, the presence of preexisting antibodies to the molecule had no impact on the anti-arthritic effects observed in this model. These data suggest that DAB486IL-2 may have therapeutic potential in the treatment of rheumatoid arthritis.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Toxina Diftérica/uso terapéutico , Interleucina-2/uso terapéutico , Receptores de Interleucina-2/efectos de los fármacos , Proteínas Recombinantes de Fusión/uso terapéutico , Animales , Artritis Experimental/diagnóstico por imagen , Artritis Experimental/patología , Toxina Diftérica/inmunología , Femenino , Interleucina-2/inmunología , Activación de Linfocitos/efectos de los fármacos , Radiografía , Ratas , Ratas Endogámicas Lew , Receptores de Interleucina-2/fisiología , Factores de TiempoAsunto(s)
Toxina Diftérica/uso terapéutico , Exotoxinas/uso terapéutico , Inmunosupresores/uso terapéutico , Inmunotoxinas/uso terapéutico , Interleucina-2/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Proteínas Recombinantes , Animales , Enfermedades Autoinmunes/terapia , Rechazo de Injerto/efectos de los fármacos , Hipersensibilidad Tardía/terapia , RatonesRESUMEN
Elevated expression of the receptor for epidermal growth factor (EGF) is a characteristic of several malignancies including those of the breast, bladder, prostate, lung, and neuroglia. To therapeutically target the cytotoxic action of diphtheria toxin to EGF receptor-expressing tumor cells, we have constructed a hybrid gene in which the sequences for the binding domain of diphtheria toxin have been replaced by those for human EGF. The resulting fusion toxins, DAB486EGF and DAB389EGF, bind specifically to the EGF receptor and inhibit protein synthesis in a variety of EGF receptor expressing human tumor cell lines with an IC50 as low as 0.1 pM. Comparisons of DAB486EGF and DAB389EGF showed that DAB389EGF was consistently 10- to 100-fold more cytotoxic than DAB486EGF. Like diphtheria toxin, the cytotoxic action of DAB389EGF results from ADP-ribosylation of elongation factor-2 and is sensitive to the action of chloroquine. Studies of the kinetics of cellular intoxication showed that a 15-min exposure of EGF receptor-expressing A431 cells to DAB389EGF results in complete protein synthesis inhibition within 4 h. Furthermore, inhibition of protein synthesis results in elimination of human tumor cell colonies. These findings show that DAB389EGF is a potential therapeutic agent for a wide variety of EGF receptor-expressing solid tumors.
Asunto(s)
Toxina Diftérica/química , Factor de Crecimiento Epidérmico/química , Receptores ErbB/metabolismo , Proteínas Recombinantes de Fusión/toxicidad , Adenosina Difosfato Ribosa/metabolismo , Muerte Celular/efectos de los fármacos , Escherichia coli/genética , Ingeniería Genética , Humanos , Técnicas In Vitro , Factor 2 de Elongación Peptídica , Factores de Elongación de Péptidos/metabolismo , Plásmidos , Proteínas Recombinantes de Fusión/metabolismoRESUMEN
DAB486IL-2 is a genetically engineered fusion protein consisting of a portion of diphtheria toxin fused to human IL-2. It is specifically cytotoxic for tumor cells which bear high-affinity IL-2 receptors (IL-2R). DAB389IL-2 is a similarly constructed hybrid protein which is smaller than DAB486IL-2 and is slightly more potent in vitro. We have developed a murine model of IL-2R-expressing malignancy to study the in vivo efficacy of these genetically engineered cytotoxins. Following intravenous administration of CP3 cells, C57BL/6 mice develop tumors which are lymphatic in distribution. When mice are injected i.v. with 10(6) CP3 cells, 90% of the animals show signs of observable tumor by day 10 to 20; death occurs in 50% of untreated animals by day 30. Intravenous treatment of mice with DAB486IL-2 (10 micrograms daily for 10 days), beginning 24 hr after administration of CP3 cells, increases mean survival time by approximately 50%. In comparative studies, DAB389IL-2 is more potent in vivo than DAB486IL-2, with approximately 90% of treated animals with no evidence of tumor at 60 days. The mechanism of action of tumor inhibition by DAB486IL-2 is specific, since treatment of animals which have IL-2R-negative EL4 tumors has not resulted in increased survival time. In addition, treatment of such tumors with DAglu53B486IL-2, a fusion protein which can bind to the IL-2R but is incapable of inhibiting protein synthesis, is ineffective.
Asunto(s)
Citotoxinas/administración & dosificación , Toxina Diftérica/administración & dosificación , Neoplasias Experimentales/tratamiento farmacológico , Receptores de Interleucina-2/metabolismo , Animales , Toxina Diftérica/química , Interleucina-2/química , Interleucina-2/metabolismo , Ratones , Ratones Desnudos , Análisis de SupervivenciaRESUMEN
The kinetics of the in vitro cytotoxicity of DAB486IL-2, a genetically engineered fusion protein containing a portion of diphtheria toxin and human interleukin-2, were examined in the C91/PL cell line, which constitutively expresses IL-2 receptors. Maximal inhibition of protein synthesis was observed by 4-6 h after DAB486IL-2 addition at a concentration of 300 ng/ml. The tissue distribution, urinary excretion, and plasma pharmacokinetics of DAB486IL-2 in the rat and its plasma pharmacokinetics in the monkey were also examined. In rats the primary site of distribution of [35S]-DAB486IL-2 outside the vasculature appears to be the liver, followed by the kidney, spleen, and lung. Persistence of radioactive material in the liver and urinary excretion of metabolic degradation products suggest that labeled protein is metabolized by hepatic tissue. Following i.v. bolus administration of DAB486IL-2, the initial serum half-life for both the rat and the monkey was approximately 5 min. The overall clearance rate of drug for the two species differed, with DAB486IL-2 being cleared from circulation 2-3 times more rapidly in the monkey. Presence of high levels of neutralizing antibodies to diphtheria toxin in the rat significantly influenced the clearance of bioactive DAB486IL-2. However, the question as to whether the presence of in vitro biological activity for the molecule is masked by the presence of antibodies cannot be clearly answered.
Asunto(s)
Toxina Diftérica/farmacocinética , Inmunotoxinas/farmacocinética , Interleucina-2/farmacocinética , Proteínas Recombinantes de Fusión/farmacocinética , Animales , Anticuerpos Antibacterianos/análisis , Células Cultivadas/efectos de los fármacos , Células Cultivadas/metabolismo , Toxina Diftérica/administración & dosificación , Toxina Diftérica/toxicidad , Toxoide Diftérico/inmunología , Femenino , Humanos , Inmunización , Inmunotoxinas/administración & dosificación , Inmunotoxinas/toxicidad , Inyecciones Intravenosas , Interleucina-2/administración & dosificación , Interleucina-2/toxicidad , Macaca fascicularis , Masculino , Pruebas de Neutralización , Ratas , Ratas Endogámicas , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/toxicidad , Radioisótopos de Azufre , Factores de Tiempo , Distribución TisularRESUMEN
A diphtheria toxin-related IL-2 fusion gene has been constructed that encodes a 68KD recombinant toxin in which the diphtheria toxin receptor-binding domain has been replaced with amino acids 2-133 of IL-2. This chimeric IL-2 toxin is cytotoxic for cells expressing the high-affinity IL-2 receptor but not for cells lacking this receptor. The ability of this IL-2 toxin to prolong allograft survival was examined in a murine vascularized, heterotopic heart transplant model in the strain combination B10.BR into C57B1/10. When given at a dose of 1.0 micrograms/day for 10 days, the IL-2 toxin significantly prolonged allograft survival in all recipients. CRM-45, a fragment of diphtheria toxin missing the binding domain, was ineffective, confirming the specificity of the therapy. The results demonstrate that this IL-2 toxin, which targets activated T cells expressing the IL-2 receptor, will prolong allograft survival, offering a new option for immunosuppressive therapy.
Asunto(s)
Toxina Diftérica , Supervivencia de Injerto/efectos de los fármacos , Trasplante de Corazón , Interleucina-2 , Proteínas Recombinantes de Fusión , Proteínas Recombinantes , Animales , Formación de Anticuerpos , Toxina Diftérica/inmunología , Toxina Diftérica/farmacocinética , Toxina Diftérica/toxicidad , Semivida , Interleucina-2/inmunología , Interleucina-2/farmacocinética , Interleucina-2/toxicidad , Riñón/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Proteínas Recombinantes de Fusión/inmunología , Proteínas Recombinantes de Fusión/farmacocinética , Proteínas Recombinantes de Fusión/toxicidad , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/toxicidadRESUMEN
De novo expression of the interleukin 2 receptor (IL-2R) is a critical and pivotal event in initiation of an immune response. Targeting the low-affinity IL-2-binding p55 subunit of the high-affinity IL-2R with the rat anti-mouse IgM monoclonal antibody M7/20 suppresses a variety of T-cell-mediated reactions, including transplant rejection, autoimmunity, and delayed-type hypersensitivity (DTH). A hybrid IL-2-toxin gene was constructed from the diphtheria toxin gene by replacing the DNA encoding the diphtheria toxin receptor-binding domain with the DNA encoding the receptor-binding domain of IL-2, and the fusion protein encoded by the hybrid gene was expressed in Escherichia coli [Williams, D.P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T.B. & Murphy, J.R. (1987) Protein Eng. 1, 493-498]. We examined the action of the chimeric IL-2-toxin fusion protein on an in vivo T-cell mediated response, DTH. The IL-2-toxin fusion protein was found to be a potent immunosuppressive agent. Treatment of mice with the IL-2-toxin blocks DTH and prevents expansion of IL-2R+ T cells. Indeed, IL-2-toxin treatment targets IL-2R+ T cells in vivo and is shown to selectively eliminate their appearance in draining lymph nodes. DTH suppression was observed even in mice possessing high titers of antibodies to diphtheria toxoid.
Asunto(s)
Toxina Diftérica/administración & dosificación , Inmunidad Celular/efectos de los fármacos , Inmunotoxinas/toxicidad , Linfocitos T/efectos de los fármacos , Animales , Toxoide Diftérico/inmunología , Citometría de Flujo , Hipersensibilidad Tardía/inmunología , Interleucina-2/administración & dosificación , Ganglios Linfáticos/citología , Ratones , Receptores Inmunológicos/metabolismo , Receptores de Interleucina-2 , Linfocitos T/clasificaciónRESUMEN
The IL-2 toxin-mediated inhibition of protein synthesis in high affinity IL-2-R-positive murine and human T cell lines has been examined. Both excess free IL-2 and mAb to the Tac epitope of the p55 subunit of IL-2-R are shown to block the action of IL-2 toxin; whereas, agents that interact with other receptors or antigens on the T cell surface have no effect. We show that IL-2 toxin, like diphtheria toxin, must pass through an acidic vesicle in order to intoxicate target T cells. Finally, we demonstrate that the IL-2 toxin-mediated inhibition of protein synthesis in both human and murine T cells that bear the high affinity IL-2-R is due to the classic diphtheria toxin fragment A-catalyzed ADP ribosylation of elongation factor 2.